From Yahoo Finance: 2025-03-28 22:31:00

Bristol-Myers Squibb Co. (BMY) saw its share prices rise by 1.90 percent on Friday to finish at $60.02 per share. The increase came after a key European regulatory committee recommended the approval of its cancer treatment Opdivo. BMY also announced plans to acquire 2seventy Bio for $286 million. The transaction is expected to be completed in the second quarter of the year. Despite the broader market downturn, BMY ranks 9th on the list of firms that ended Friday strong.

Wall Street’s main indices closed the trading week in negative territory due to global trade tensions. The Nasdaq fell by 2.70 percent, the S&P 500 by 1.97 percent, and the Dow Jones by 1.69 percent. Despite this, 10 individual stocks performed well, with three reaching all-time highs. The list was compiled based on stocks with a $2-billion market cap and $5 million in trading volume.

Overall, Bristol-Myers Squibb Co. (BMY) experienced a positive day on Friday, with its share prices increasing by 1.90 percent to $60.02 per share. This rise was attributed to the backing of a key European regulatory committee for its cancer treatment Opdivo. Additionally, BMY announced plans to acquire 2seventy Bio for $286 million. The transaction is expected to be completed in the second quarter of the year.



Read more at Yahoo Finance: Why Bristol-Myers Squibb Co. (BMY) Went Up On Friday?